Navigation Links
Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
Date:11/5/2007

f TPI 287 when delivered orally in subcutaneous mouse xenograft models of both pancreatic cancer and glioblastoma multiforme.

"All of us at Tapestry are encouraged by the emerging safety and efficacy profile of TPI 287." commented Leonard Shaykin, Chairman and CEO of Tapestry. "Prior to year end we anticipate initiating both our oral PK Phase 1b trial in multiple tumor types and our third Phase 2 trial for TPI 287 in glioblastoma multiforme."

Conference Call Information

Tapestry will host a conference call at 12:00 p.m. Eastern Time on November 5, 2007 to discuss 2007 third quarter results and recent corporate developments. To participate in the conference call, please dial 800-798-2864 (domestic) or 617-614-6206 (international) and reference the access code 50821900. A replay of the call will be available from 2:00 p.m. Eastern Time on November 5, 2007 until November 12, 2007 at midnight Eastern Time. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 55489394. A live audio webcast of the call will also be available on the "Investors" section of the Company's website, http://www.tapestrypharma.com. An archived webcast will be available on the Tapestry website for approximately 30 days after the event.

About Tapestry Pharmaceuticals, Inc.

Tapestry Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer.

For more information about Tapestry and its technologies, visit Tapestry's website at http://www.tapestrypharma.com.

About TPI 287

TPI 287, a proprietary next-generation taxane, is Tapestry's lead clinical compound. This compound was designed to overcome multiple drug resistance in solid tumors that are innately resistant to taxane therapy or have become resistan
'/>"/>

SOURCE Tapestry Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Tapestry to Host Conference Call on November 5th to Discuss Third Quarter 2007 Financial Results
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Dr. Ingrid Warmuth and Anamaria Newport, MHS, PA-C, with locations ... an Open House at their Swedesboro location, 95 Woodstown Road. ... 10 AM to 2 PM. , During the open ... be on hand to talk to people about the benefits ... cosmetic consultations. There will also be specials offered, such as ...
(Date:5/24/2013)... 2013 Senomyx , Inc. (NASDAQ: ... technologies to discover, develop, and commercialize novel flavor ingredients, ... Ph.D., the Company,s Vice President, Biology and ... Corporate Communications, will present an overview of Senomyx,s technology ... Eastern Time (7:25 a.m. Pacific Time) during the Citi ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a ... research and development, sales and marketing of premium ... today that it is awarding exclusive Vestiage territories ... Reluma Skin Illuminating Facial Care. Qualified applicants can ... an email to info(at)vestiageinc(dot)com and putting RELUMA in ...
(Date:5/23/2013)... , May 23, 2013 Venaxis, Inc. (Nasdaq: ... focused on obtaining FDA clearance and commercializing its rapid, ... the pricing of an underwritten public offering of 10,000,000 ... purchase 3,500,000 shares of its common stock at an ... public offering price of $1.25 per share and related ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
... AstraZeneca Exec to Lead Hong Kong-based subsidiary Pangu BioPharmaSAN ... biopharmaceutical company focused on discovery and development of an ... multiple disease indications, today announced that Dr. James Cai ... Clinical Development at aTyr Pharma and President of Pangu ...
... & Sullivan recognizes BioTrove, Inc. with the 2009 ... Strategy Leadership of the Year. The annual ... most significant drug-discovery innovations and acknowledgments by life ... specializing in drug acceleration and pipeline assessment technologies, ...
... One Corporation (Pink Sheets: MNCN), announced today that its ... serve as the company,s Chief Financial Officer, effective March ... said, "Pat brings a strong background in finance to ... financial expertise will be great assets to Mach One ...
Cached Biology Technology:Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia 2Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia 3Frost & Sullivan Lauds BioTrove for Providing Research-Enabling Life Sciences and Drug Discovery Technologies 2Frost & Sullivan Lauds BioTrove for Providing Research-Enabling Life Sciences and Drug Discovery Technologies 3Frost & Sullivan Lauds BioTrove for Providing Research-Enabling Life Sciences and Drug Discovery Technologies 4Mach One Announces Appointment of Chief Financial Officer 2
(Date:5/23/2013)... and fastest growing open-access publishers, announces the launch ... and Biotechnology . , A broad scope ... and Biotechnology will provide a single open-access ... research to be disseminated and discussed. , ... provide an open-science and interactive web platform for ...
(Date:5/22/2013)... cell powered buses, including a team from Simon ... processes and bus membrane durability. , The team ... in the operating cycle of the bus on ... study, led by SFU graduate student Natalia MaCauley, ... Burnaby-based Ballard Power Systems and funded by Automotive ...
(Date:5/22/2013)... The discovery of potential environmental and human health ... batteries each year has led scientists to recommend ... reuse of lithium-ion (Li-ion) battery materials. That,s the ... journal Environmental Science & Technology . , ... Li-ion batteries have become mainstays for powering everything ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in Bioengineering and Biotechnology 2Tests lead to doubling of fuel cell life 2
... counters prevailing thought, a study in mice has found ... "fat-burning" can actually increase energy expenditure and help lower ... the JBC, might lead to some new ... warm-blooded animals need to continually "burn fat" in order ...
... filling such an important niche in ocean communities that ... however, that sea otters can have even farther-reaching effects ... of another top predator: the bald eagle. ... of 250 feet and function much like trees in ...
... 2008) To help improve the success of oyster ... Center for Environmental Science researcher Dr. Elizabeth North is ... study to determine when oysters spawn and where their ... is supported by a $750,000 competitive grant from the ...
Cached Biology News:Making metabolism more inefficient can reduce obesity 2Decline in Alaskan sea otters affects bald eagles' diet 2Decline in Alaskan sea otters affects bald eagles' diet 3
Rat Hepatocytes (RH) (>3,000,000 cells)...
... of proteomics demands the detection of very ... of the AXIMA-CFRplus with improved resolution (20,000) ... provides increased confidence in protein identification. The ... sensitivity, automated sample target handling and the ...
...
... The new MALDI O-TOF creates a ... on an orthogonal platform that has been ... the University of Manitoba. , As the ... orthogonal design and collisional cooling, the prOTOF ...
Biology Products: